Increased risk of everolimus-associated acute kidney injury in cancer patients with impaired kidney function

BACKGROUND: Everolimus was recently introduced as a second-line treatment for renal cell carcinoma (RCC) and many other cancers. Several prospective studies have shown that serum creatinine levels are increased in a significant proportion of patients receiving everolimus. However, data on the occurr...

Descripción completa

Detalles Bibliográficos
Autores principales: Ha, Sung Hae, Park, Ji Hyeon, Jang, Hye Ryoun, Huh, Wooseong, Lim, Ho-Yeong, Kim, Yoon-Goo, Kim, Dae Joong, Oh, Ha Young, Lee, Jung Eun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265483/
https://www.ncbi.nlm.nih.gov/pubmed/25466872
http://dx.doi.org/10.1186/1471-2407-14-906

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265483/
https://www.ncbi.nlm.nih.gov/pubmed/25466872
http://dx.doi.org/10.1186/1471-2407-14-906

Ejemplares similares